Methopromazine

Base Information

• Chemical Name: Methopromazine
• CAS No.: 61-01-8
• Molecular Formula: C18H22 N2 O S
• Molecular Weight: 314.451
• European Community (EC) Number: 200-497-6
• UNII: A6F645Q9HQ
• DSSTox Substance ID: DTXSID90209843
• Nikkaji Number: J4.813E
• Wikidata: Q27273690
• NCI Thesaurus Code: C174606
• ChEMBL ID: CHEMBL2110655
• Mol file: 61-01-8.mol

Synonyms:methopromazine;methopromazine maleate (1:1);methopromazine maleate (1:2);methoxypromazine

Chemical Property of Methopromazine

Chemical Property:

• Vapor Pressure: 1.04E-08mmHg at 25°C
• Melting Point: 44-48°
• Refractive Index: 1.5950 (estimate)
• Boiling Point: 461.8°C at 760 mmHg
• Flash Point: 233.1°C
• PSA: 41.01000
• Density: 1.143g/cm³
• LogP: 4.31460
• XLogP3: 4.9
• Hydrogen Bond Donor Count: 0
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 5
• Exact Mass: 314.14528450
• Heavy Atom Count: 22
• Complexity: 352

Purity/Quality:

99% ^*data from raw suppliers

2-MethoxyPromazine ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC
• Uses: A Promazine

Technology Process of Methopromazine

There total 9 articles about Methopromazine which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 33.0%

2-methoxy-10H-phenothiazine (1771-18-2) + 3-(N,N'-dimethylamino)propyl methanesulfonate hydrochloride (52413-48-6) → 2-methoxypromazine (61-01-8)

Guidance literature:

2-methoxy-10H-phenothiazine; With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 0 ℃;

3-(N,N'-dimethylamino)propyl methanesulfonate hydrochloride; In N,N-dimethyl-formamide; mineral oil; at 0 - 20 ℃;

DOI:10.1016/j.tetlet.2020.152582

Reference yield: 23.0%

2-methoxy-10H-phenothiazine (1771-18-2) + 3-(dimethylamino)propyl chloride hydrochloride (5407-04-5) → 2-methoxypromazine (61-01-8)

Guidance literature:

2-methoxy-10H-phenothiazine; With sodium hydride; In N,N-dimethyl-formamide;

3-(dimethylamino)propyl chloride hydrochloride; In N,N-dimethyl-formamide; at 20 ℃; for 1.5h;

DOI:10.1016/j.tetlet.2020.152582

Reference yield:

2-methoxy-10H-phenothiazine (1771-18-2) + 3-(Dimethylamino)propyl chloride (109-54-6) → 2-methoxypromazine (61-01-8)

Guidance literature:

With sodium amide; xylene;

upstream raw materials:

2-methoxy-10H-phenothiazine

3-(Dimethylamino)propyl chloride

N'-[2-(2-bromo-phenylsulfanyl)-5-methoxy-phenyl]-N,N-dimethyl-propanediyldiamine

methanol

Refernces

Design and synthesis of some novel quinoline derivatives as anticancer and radiosensitizing agents targeting VEGFR tyrosine kinase

10.1002/jhet.749

The study investigates the synthesis and evaluation of novel quinoline derivatives for their anticancer and radiosensitizing properties. The researchers synthesized a series of quinoline derivatives (6–12) and pyrimido[4,5-b]quinoline derivatives (16–20) to assess their potential as inhibitors of vascular endothelial growth factor receptor tyrosine kinase (VEGFR-TK), which is implicated in cancer cell proliferation and angiogenesis. The compounds were evaluated for their in vitro anticancer activity against the human breast cancer cell line MCF7, which overexpresses VEGFR. Notably, compounds 6 and 7 exhibited significant cytotoxic activity, with IC50 values of 8.5 μM and 21.9 μM, respectively, surpassing the reference drug doxorubicin (IC50 = 32.02 μM). These two compounds were further tested for their ability to enhance the cell-killing effect of gamma radiation, showing a synergistic decrease in IC50 values when combined with radiation. The study also utilized molecular modeling to generate a pharmacophore hypothesis for VEGFR-TK inhibitors and conducted docking studies to explore the binding modes of the synthesized compounds, revealing that compound 7 had a binding mode similar to the known VEGFR-TK inhibitor Vatalanib. The results suggest that some of the synthesized compounds may act as VEGFR-TK inhibitors, contributing to their anticancer activity and radiosensitizing effects.